Physician profile
Ranvir Singh
NPI 1639289465
$5,671.08
in general payments reported to CMS, 2019-2025
34 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $302 · 2021: $246 · 2022: $840 · 2023: $1,191 · 2024: $1,064 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,474 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,474.29 |
| Education | $114.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,875.36 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Genzyme Corporation | $413.27 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $393.64 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $383.82 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $324.85 | 2019-2025 | Entyvio |
| Pfizer INC. | $246.09 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $223.64 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.36 | 2019-2025 | Trulance, Xifaxan |
| Qol Medical, LLC | $178.62 | 2020-2025 | Sucraid, Sucraid |
| Celgene Corporation | $141.18 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $138.78 | 2019-2025 | Epclusa |
| Intercept Pharmaceuticals, INC. | $114.36 | 2022-2025 | Ocaliva |
| Mallinckrodt Hospital Products INC. | $110.85 | 2023 | Terlivaz |
| Lilly USA, LLC | $107.19 | 2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $106.23 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $89.39 | 2019-2020 | |
| Medtronic USA, INC. | $78.73 | 2020 | |
| Daiichi Sankyo INC. | $57.80 | 2022-2023 | Injectafer |
| Ucb, INC. | $53.93 | 2019 | |
| Phathom Pharmaceuticals, INC. | $50.89 | 2023-2025 | Voquezna |
| Allergan, INC. | $46.59 | 2019 | |
| Nestle Healthcare Nutrition INC. | $46.39 | 2022 | |
| Ardelyx, INC. | $39.89 | 2023-2024 | Ibsrela |
| Organon LLC | $39.80 | 2024-2025 | Renflexis, Hadlima |
| Medtronic, INC. | $32.83 | 2023 | Bravo |
| Aimmune Therapeutics, INC. | $30.08 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $26.83 | 2024 | Iqirvo |
| Ferring Pharmaceuticals INC. | $26.66 | 2019-2024 | Rebyota |
| Amgen INC. | $23.50 | 2020 | |
| Madrigal Pharmaceuticals | $17.75 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.17 | 2023 | |
| Fresenius Kabi USA, LLC | $16.17 | 2023 | Idacio |
| Celltrion USA INC. | $15.19 | 2024 | Zymfentra |
| Braintree Laboratories, INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranvir Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.